keyword
MENU ▼
Read by QxMD icon Read
search

Spiromax

keyword
https://www.readbyqxmd.com/read/28732829/budesonide%C3%A2-%C3%A2-formoterol-delivered-via-spiromax-%C3%A2-for-the-management-of-asthma-and-copd-the-potential-impact-on-unscheduled-healthcare-costs-of-improving-inhalation-technique-compared-with-turbuhaler-%C3%A2
#1
A Lewis, S Torvinen, P N R Dekhuijzen, H Chrystyn, A Melani, Y Zöllner, K Kolbe, A T Watson, M Blackney, A Plich
BACKGROUND: Fixed-dose combinations of inhaled corticosteroids and long-acting β2 agonists are commonly used for the treatment of asthma and COPD. However, the most frequently prescribed dry powder inhaler delivering this medicine - Symbicort(®) (budesonide and formoterol, BF) Turbuhaler(®) - is associated with poor inhalation technique, which can lead to poor disease control and high disease management costs. A recent study showed that patients make fewer inhaler errors when using the novel DuoResp(®) (BF) Spiromax(®) inhaler, compared with BF Turbuhaler(®)...
August 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/28332886/inhaler-technique-mastery-and-maintenance-in-healthcare-professionals-trained-on-different-devices
#2
Sinthia Bosnic-Anticevich, Christina Callan, Henry Chrystyn, Federico Lavorini, Vasilis Nikolaou, Vicky Kritikos, P N Richard Dekhuijzen, Nicolas Roche, Leif Bjermer, Cynthia Rand, Nicholas Zwar, David B Price
OBJECTIVE: Healthcare professionals (HCPs) are required to assess and train patients in the correct use of inhalers but are often unable to demonstrate correct technique themselves. We sought to assess the level of training required for HCPs to master and maintain device mastery when using two different dry powder inhalers (DPIs). METHODS: We conducted a randomized, un-blinded, crossover study in undergraduate HCPs who undertook a six-step training procedure (intuitive use, patient information leaflet, instructional video, individual tuition from expert, then two repeats of individual tuition) for the use of Turbuhaler® (an established device) and Spiromax® (a newer device, reportedly easier to use)...
March 23, 2017: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/28228660/estimating-the-economic-consequences-of-an-increased-medication-adherence-due-to-a-potential-improvement-in-the-inhaler-technique-with-spiromax-%C3%A2-compared-with-turbuhaler-%C3%A2-in-patients-with-moderate-to-severe-chronic-obstructive-pulmonary-disease-in-spain
#3
Josep Darbà, Gabriela Ramírez, Juan L García-Rivero, Sagrario Mayoralas, José Francisco Pascual, Diego Vargas, Adi Bijedic
OBJECTIVE: The objective of this study was to estimate the economic impact of the introduction of DuoResp(®) Spiromax(®), budesonide/formoterol fixed-dose combination (FDC), focusing on an increase in medication adherence due to an enhancement of the inhalation technique for the treatment of COPD patients in Spain and 5 regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia. METHODS: A 4-year budget impact model was developed for the time period of 2015-2018...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/27972275/the-potential-to-improve-inhalation-technique-in-patients-with-asthma-or-copd-by-switching-from-symbicort%C3%A2-turbuhaler%C3%A2-budesonide-formoterol-to-duoresp%C3%A2-spiromax%C3%A2-estimated-impact-on-the-number-and-cost-of-unscheduled-healthcare-events-in-poland
#4
A Watson, P Bijos, R Ludwikowski, A Lewis, M Blackney, S Torvinen, A Plich
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971520/real-life-persistence-of-budesonide-formoterol-spiromax-for-the-management-of-asthma-and-copd-in-the-uk
#5
H Benhaddi, M Van Der Tol, D Price, M Batsiou, R Ariely
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27853177/difference-in-resistance-to-humidity-between-commonly-used-dry-powder-inhalers-an-in-vitro-study
#6
Christer Janson, Thomas Lööf, Gunilla Telg, Georgios Stratelis, Folke Nilsson
Multi-dose dry powder inhalers (DPIs) are commonly used in asthma and chronic obstructive lung disease (COPD) treatment. A disadvantage is their sensitivity to humidity. In real life, DPIs are periodically exposed to humid conditions, which may affect aerosol characteristics and lung deposition. This study compared DPI aerosol performance after exposure to humidity. Budesonide (BUD) inhalers (Turbuhaler; Novolizer; Easyhaler) and budesonide/formoterol (BUD/FORM) inhalers (Turbuhaler; Spiromax; Easyhaler) were stored in 75% relative humidity (RH) at both ambient temperature and at -0 °C...
November 17, 2016: NPJ Primary Care Respiratory Medicine
https://www.readbyqxmd.com/read/27660476/a-budget-impact-analysis-of-spiromax-%C3%A2-compared-with-turbuhaler-%C3%A2-for-the-treatment-of-moderate-to-severe-asthma-a-potential-improvement-in-the-inhalation-technique-to-strengthen-medication-adherence-could-represent-savings-for-the-spanish-healthcare-system
#7
Josep Darbà, Gabriela Ramírez, Juan L García-Rivero, Sagrario Mayoralas-Alises, José Francisco Pascual, Albert Roger, Diego Vargas, Adi Bijedic
OBJECTIVE: To assess the economic impact of the introduction of DuoResp(®) Spiromax(®) by focusing on a potential improvement in the inhalation technique to strengthen medication adherence for the treatment of moderate to severe asthmatics in Spain and five Spanish regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia. METHODS: A 4-year budget impact model was developed for the period 2015-2018 from the Spanish Healthcare System perspective. Budesonide-formoterol fixed-dose combination delivered by Turbuhaler(®) was considered to be the most appropriate comparator for assessing the budget impact with the introduction of DuoResp(®) Spiromax(®)...
2016: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/27344046/onset-of-action-of-budesonide-formoterol-spiromax-%C3%A2-compared-with-budesonide-formoterol-turbuhaler-%C3%A2-in-patients-with-copd
#8
Mario Cazzola, Josuel Ora, Alessanda Di Paolo, Ermanno Puxeddu, Luigino Calzetta, Paola Rogliani
Budesonide/formoterol (BF) is available in two delivery systems, the dry powder inhaler (DPI) Turbuhaler and a pressurized metered dose inhaler (pMDI) for use in patients with asthma or chronic obstructive pulmonary disease (COPD). Spiromax DPI was recently developed as an alternative to Turbuhaler DPI. In the present study, we examined whether there is a difference in the onset of bronchodilatation between BF 320/9 μg delivered by Spiromax and BF 320/9 μg delivered by Turbuhaler in 16 outpatients with stable moderate-to-severe COPD...
August 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27026804/evaluation-of-inhaler-handling-errors-inhaler-perception-and-preference-with-spiromax-easyhaler-and-turbuhaler-devices-among-healthy-finnish-volunteers-a-single-site-single-visit-crossover-study-finhaler
#9
Niklas Sandler, Jenny Holländer, Disa Långström, Pekka Santtila, Anni Saukkonen, Saku Torvinen
INTRODUCTION: Correct inhaler technique and device preference are positively correlated with improved adherence and clinical outcomes. This study was designed to investigate inhaler technique mastery and device preference for three different dry powder inhalers, Spiromax, Easyhaler and Turbuhaler. METHODS: This was a single site, single visit, crossover study assessing device mastery, handling errors and preference using empty Spiromax, Easyhaler and Turbuhaler devices in healthy adult Finnish volunteers...
2016: BMJ Open Respiratory Research
https://www.readbyqxmd.com/read/26987997/a-randomized-double-blinded-double-dummy-efficacy-and-safety-study-of-budesonide-formoterol-spiromax%C3%A2-compared-to-budesonide-formoterol-turbuhaler%C3%A2-in-adults-and-adolescents-with-persistent-asthma
#10
RANDOMIZED CONTROLLED TRIAL
J Christian Virchow, Roberto Rodriguez-Roisin, Alberto Papi, Tushar P Shah, Gokul Gopalan
BACKGROUND: Budesonide and formoterol (BF) Spiromax® is a dry powder inhaler designed to deliver BF with maximum ease of use for patients with asthma or chronic obstructive pulmonary disease. METHODS: A phase 3b, 12-week, multicenter, double-blind, double-dummy, randomized, controlled trial in patients (≥12 years) with persistent asthma. PRIMARY OBJECTIVE: to demonstrate non-inferiority of twice-daily BF Spiromax 160/4.5 mcg to BF Turbuhaler® 200/6 mcg in change from baseline in weekly average of daily trough morning peak expiratory flow (PEF)...
March 17, 2016: BMC Pulmonary Medicine
https://www.readbyqxmd.com/read/26532783/the-budget-impact-of-duoresp%C3%A2-spiromax%C3%A2-compared-with-commonly-prescribed-dry-powder-inhalers-for-the-management-of-asthma-and-chronic-obstructive-pulmonary-disease-in-italy-estimated-impact-of-inhalation-technique
#11
S Torvinen, J Nicolai, S Pulimeno, L di Nola, G M Bruno, G L Colombo, S Di Matteo, M C Valentino, A Lewis, M Blackney, L Burgio, A Plich
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/26532051/evaluation-of-inhaler-perception-and-preference-of-spiromax%C3%A2-easyhaler%C3%A2-and-turbuhaler%C3%A2-devices-finhaler
#12
N Sandler, J Holländer, D Långström, P Santtila, A Saukkonen, S Torvinen
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/26532050/evaluation-of-inhaler-technique-mastery-and-handling-errors-with-spiromax%C3%A2-easyhaler%C3%A2-and-turbuhaler%C3%A2-devices-finhaler
#13
N Sandler, J Holländer, D Långström, P Santtila, A Saukkonen, S Torvinen
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/26531978/the-potential-for-improved-inhalation-technique-with-duoresp%C3%A2-spiromax%C3%A2-budesonide-formoterol-fumarate-dihydrate-compared-with-commonly-prescribed-dry-powder-inhalers-for-the-management-of-asthma-and-chronic-obstructive-pulmonary-disease-in-spain-estimated
#14
A Lewis, M Blackney, L Garcia Bujalance, R Sánchez-de la Rosa, S Torvinen, A Plich
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/26531970/estimating-the-economic-consequences-of-an-increased-medication-compliance-due-to-a-potential-improvement-of-the-inhaler-technique-with-spiromax%C3%A2-compared-with-turbuhaler%C3%A2-in-moderate-to-severe-patients-with-copd-in-spain
#15
J Darba, G Ramírez, S Gómez, A Bijedic, R Sánchez-de la Rosa, L Garcia-Bujalance, S Torvinen
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/26531968/a-budget-impact-analysis-to-estimate-the-economic-consequences-of-an-increase-of-medication-compliance-related-to-a-potential-improvement-of-the-inhalation-technique-with-spiromax%C3%A2-compared-with-turbuhaler%C3%A2-in-moderate-to-severe-asthmatic-patients-in-spain
#16
J Darba, G Ramírez, S Gómez, A Bijedic, R Sánchez-de la Rosa, L Garcia-Bujalance, S Torvinen
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/26352860/spiromax-a-new-dry-powder-inhaler-dose-consistency-under-simulated-real-world-conditions
#17
Giorgio Walter Canonica, Jan Arp, Johan René Keegstra, Henry Chrystyn
BACKGROUND: Spiromax(®) is a novel dry powder inhaler for patients with asthma or chronic obstructive pulmonary disease (COPD). The studies presented here provide further data on attributes (in vitro dosing consistency with budesonide-formoterol (DuoResp) Spiromax; flow rates through empty versions of the Spiromax and Turbuhaler inhaler) of importance to patients with asthma or COPD. METHODS: Dose-delivery studies were performed using low-, middle-, and high-strength DuoResp Spiromax...
October 2015: Journal of Aerosol Medicine and Pulmonary Drug Delivery
https://www.readbyqxmd.com/read/26043823/effect-of-inhalation-profile-and-throat-geometry-on-predicted-lung-deposition-of-budesonide-and-formoterol-bf-in-copd-an-in-vitro-comparison-of-spiromax-with-turbuhaler
#18
COMPARATIVE STUDY
Henry Chrystyn, Guilherme Safioti, Johan René Keegstra, Gokul Gopalan
Successful delivery of inhalation medication to the lungs can be affected by the inhalation manoeuvre used. Conventional in-vitro testing of the emitted dose from a dry powder inhaler (DPI) uses a vacuum pump to simulate an inhalation. We have adapted this method by replacing the pump with patient inhalation profiles and an anatomical throat. Three anatomical throat sizes and three inhalation profiles were used. The profiles represented the 10th, 50th and 90th percentiles of peak inhalation flow and acceleration of flow from a population of 50 COPD patients inhaling through empty Spiromax and Turbuhaler devices...
August 1, 2015: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/26042485/bioequivalence-of-budesonide-plus-formoterol-bf-spiromax%C3%A2-and-bf-turbohaler%C3%A2-with-and-without-charcoal-block-in-healthy-volunteers
#19
RANDOMIZED CONTROLLED TRIAL
Lori Weisfeld, Youyi Shu, Tushar P Shah
OBJECTIVE: Budesonide formoterol (BF) Spiromax® is a breath-actuated dry-powder inhaler designed to deliver similar combinations of budesonide and formoterol as Symbicort® Turbohaler®. We performed two studies to demonstrate pharmacokinetic (PK) equivalence of BF Spiromax with BF Turbohaler. MATERIALS AND METHODS: Two single-center, open-label, randomized, 5-period crossover studies were performed. The first study compared BF Spiromax 160/4.5 μg with BF Turbohaler 200/6 μg, while the second study compared BF Spiromax 320/9 μg with BF Turbohaler 400/12 μg...
July 2015: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/25927483/inhalation-characteristics-of-asthma-patients-copd-patients-and-healthy-volunteers-with-the-spiromax%C3%A2-and-turbuhaler%C3%A2-devices-a-randomised-cross-over-study
#20
RANDOMIZED CONTROLLED TRIAL
Wahida Azouz, Philip Chetcuti, Harold Hosker, Dinesh Saralaya, Henry Chrystyn
BACKGROUND: Spiromax® is a novel dry-powder inhaler containing formulations of budesonide plus formoterol (BF). The device is intended to provide dose equivalence with enhanced user-friendliness compared to BF Turbuhaler® in asthma and chronic obstructive pulmonary disease (COPD). The present study was performed to compare inhalation parameters with empty versions of the two devices, and to investigate the effects of enhanced training designed to encourage faster inhalation. METHODS: This randomised, open-label, cross-over study included children with asthma (n = 23), adolescents with asthma (n = 27), adults with asthma (n = 50), adults with COPD (n = 50) and healthy adult volunteers (n = 50)...
2015: BMC Pulmonary Medicine
keyword
keyword
94388
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"